ObjectiveTo explore a new simple epicanthoplasty method fit for various types of epicanthus with inconspicuous scar after operation.Methods As the latest studies showed that the anatomical structure of epicanthus is mainly due to the eyelid orbicularis muscle's dislocation at the starting point of the medial canthal tendon,which affects the skin appearance,rather than the traditional view that was merely the excess skin,we released the adhesions between the skin and the inner canthus orbicularis muscle,and corrected the dislocation of orbicularis muscle that was key to the operation,incised along with the line A′→B→A″→ C in the field of interior canthus,separated the subcutaneous fascia tissue,relaxed the subcutaneous fibrous cord,disconnect the orbicularis muscle's attachment point in the inner canthal fold,and then sutured and folded the inner canthal ligament.After sewing up point A′ and point A″,the released skin retracted naturally and formed a new inner canthal contour.ResultsFrom June 2008 to June 2009,57 cases of epicanthus patients accepted this surgery.After operation,the appearance of canthus was nice.Eye fissure got widen,and the scar was not obvious.Also there was a high satisfactory rate.ConclusionsThis method has a broad range of applications.It is suitable for various types of epicanthus correction.

OBJECTIVEThe past studies found that the treatment of chronic myeloid leukemia (CML) with imatinib can induce the macrocytic anemia, moreover the incidence of anemia increases along with enhancement of imatinib concentration. This study was aimed to evaluate the potential relation of erythrocyte mean corpuscular volume (MCV) increase after the treatment with tyrosine kinase inhibitors (TKI) with the therapeutic response in patients with CML-chronic phase (CML-CP).

METHODSThe clinical and hematologic data including MCV, molecular and cytogenetic response of 119 patients with CML-CP were collected after treatment with TKIs, and the relation of MCV changes after treatment with the clinical characteristics and therapeutic efficacy for patients with CML-CP was analyzed.

RESULTSThe MCV in patients treated with TKIs for 12 months significantly increased as compared with that at initial diagnosis (P<0.05). The proportion of patients with increased MCV in group of complete cytogenetic response (CCyR) was significantly higher than that in group of non-CCyR (P<0.05). As compared with decreased MCV group, the patients in increased MCV group much more easily achieved CCyR after treatment for 6, 12 months (P<0.05, P<0.05) respectively, furthermore, much more easily maintained MMR (P<0.05).

CONCLUSIONThe MCV as a parameter which is easily acquired may be a new marker for prodecting the therapeutic response of patients treated with TKIs.

Antineoplastic Agents ; Erythrocyte Indices ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Protein Kinase Inhibitors ; Treatment Outcome